Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2023

Open Access 22-07-2023 | Multiple Myeloma | short review

ASH highlights 2022—multiple myeloma

Authors: Lina Z. Rüsing, Hermine Agis, Maria Krauth

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Login to get access

Summary

The 64th annual meeting was held in New Orleans, Louisiana from December 10–13, 2022. More than 150 abstracts concerning multiple myeloma have been presented, mirroring the rapid progression, and deepening of our understanding of this disease.
Evolution in treatment options includes new therapeutic regimens incorporating established drugs as well as entirely newly discovered substances, targeting malignant plasma cells utilizing the power of the immune system. In the following, a personal shortcut of hot topics is presented, focusing on data from large clinical trials which have the potency to change clinical practice as well as on new treatment options which may impact future strategies to achieve deep and durable responses aiming to pave the way to potential cure.
Literature
1.
Perrot A, Facon T, Plesner T, Usmani S, Kumar SK, Bahlis NJ, et al. Health-related quality of life for frail transplant-ineligible patients with newly diagnosed multiple myeloma treated with Daratumumab, Lenalidomide and Dexamethasone: subgroup analysis of MAIA trial. Blood. 2022;140(Supplement 1):1142–5.CrossRef
2.
Manier S, Corre J, Hulin C, Laribi K, Araujo C, Pica G‑M, et al. A dexamethasone sparing-regimen with daratumumab and lenalidomide in frail patients with newly-diagnosed multiple myeloma: efficacy and safety analysis of the phase 3 IFM2017-03 trial. Blood. 2022;140(Supplement 1):1369–70.CrossRef
3.
Pawlyn C, Menzies T, Davies FE, de Tute RM, Henderson R, Cook G, et al. Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant—data from the myeloma XI trial. Blood. 2022;140(Supplement 1):1371–2.CrossRef
4.
Chari A, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts): final analysis of griffin among clinically relevant subgroups. Blood. 2022;140(Supplement 1):7278–81.CrossRef
5.
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–45.CrossRefPubMedPubMedCentral
6.
Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885–8.CrossRefPubMed
7.
8.
Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–30.CrossRefPubMedPubMedCentral
9.
Kaiser MF, Hall A, Smith I, de Tute RM, Roberts S, Ingleson E, et al. Extended intensified post-ASCT consolidation with daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) for ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL): the UK optimum/Muknine trial. Blood. 2022;140(Supplement 1):1833–5.CrossRef
10.
Kaiser MF, Hall A, Walker K, Newnham N, de Tute RM, Roberts S, et al. Daratumumab, cyclophosphamide, bortezomib, lenalidomide, dexamethasone (Dara-CVRd), V‑augmented Autologous stem cell transplant (V-ASCT) and Dara-Vrd consolidation in ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) and primary plasma cell leukemia (pPCL) compared with myeloma XI/XI+ trial treatment for Uhir MM: the UK optimum/Muknine trial. Blood. 2021;138(Supplement 1):465.CrossRef
11.
Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–8.CrossRefPubMed
12.
Usmani SZ, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–664.CrossRefPubMed
13.
Searle E. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC‑2, a phase1b, Multicohort study. American Society of Hematology Meeting. 2022.
14.
Bahlis NJ. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B‑cell maturation antigen (BCMA)-directed therapies: results from cohort a of the magnetismm‑3 study. American Society of Hematology Meeting. 2022.
15.
Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.CrossRefPubMed
16.
Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja J, Oriol A, et al. Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): phase 1/2 results from MonumenTAL‑1. Blood. 2022;140(Supplement 1):384–7.CrossRef
17.
Wong SW, Bar N, Paris L, Hofmeister CC, Hansson M, Santoro A, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T‑cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood. 2022;140(Supplement 1):400–2.CrossRef
18.
Carlo-Stella C, Mazza R, Manier S, Facon T, Yoon S‑S, Koh Y, et al. RG6234, a GPRC5dxCD3 T‑cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. Blood. 2022;140(Supplement 1):397–9.CrossRef
19.
Bruins WSC, Rentenaar R, Collins S, Sampson JF, Van De Donk NW, Zweegman S, et al. Modakafusp alfa (TAK-573), a novel CD38-targeting attenuated interferon-alpha immunocytokine, kills MM cells via NK cell activation. Blood. 2022;140(Supplement 1):4236–7.CrossRef
20.
Richardson PG, Trudel S, Quach H, Popat R, Lonial S, Orlowski RZ, et al. Mezigdomide (CC-92480), a potent, novel cereblon E3 Ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the dose-expansion phase of the CC-92480-MM-001 trial. Blood. 2022;140(Supplement 1):1366–8.CrossRef
21.
Usmani S, Patel K, Hari P, Berdeja J, Alsina M, Vij R, et al. KarMMa‑2 cohort 2a: efficacy and safety of Idecabtagene vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation. Blood. 2022;140(Supplement 1):875–7.CrossRef
22.
Costa LJ, Kumar SK, Atrash S, Liedtke M, Kaur G, Derman BA, et al. Results from the first phase 1 clinical study of the B‑cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood. 2022;140(Supplement 1):1360–2.CrossRef
Metadata
Title
ASH highlights 2022—multiple myeloma
Authors
Lina Z. Rüsing
Hermine Agis
Maria Krauth
Publication date
22-07-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00898-x

Other articles of this Issue 3/2023

memo - Magazine of European Medical Oncology 3/2023 Go to the issue

short review

How the long-term follow-up is organized in young adult survivors of childhood cancer

case report

Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin

review

ASH 2022—new developments in acute myeloid leukemia

editorial

American Society of Hematology meeting update

editorial

Head and neck cancer revisited

original report

Assessment of nutritional status using objective and subjective methods in Greek patients with cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits